Switzerland-based gene-editing biotech firm CRISPR Therapeutics has filed with the US SEC to list its IPO on the Nasdaq with a view to raising $90m in the public arena, having already raised millions in private funding. -but he requested a fast-track process and received the official patent in April 2014. The company is seeking to raise up to $100m, which would be used for research and development of new treatments using gene editing. CRISPR's move follows other listings of notable biotech start-ups, Editas and Intellia. The firm already operates a joint venture with Germany’s Bayer (Casebia Therapeutics) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin-related programmes.
Switzerland-based gene-editing biotech firm CRISPR Therapeutics has filed with the US SEC to list its IPO on the Nasdaq with a view to raising $90m in the public arena, having already raised millions in private funding. The company is seeking to raise up to $100m, which would be used for research and development of new treatments using gene editing. CRISPR's move follows other listings of notable biotech start-ups, Editas and Intellia. The firm already operates a joint venture with Germany’s Bayer (Casebia Therapeutics) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin-related programmes.